Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).

Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M; IMPAACT P1110 Protocol Team.

J Acquir Immune Defic Syndr. 2020 Jan 6. doi: 10.1097/QAI.0000000000002294. [Epub ahead of print]

PMID:
31913995
2.

A Novel HIV-1 Nef Mutation in a Primary Pediatric Isolate Impairs MHC-Class I Downregulation and Cytopathicity.

Ali A, Furler RL, Pedroza-Martins L, Colantonio AD, Anisman-Posner D, Bryson Y, Yang OO, Uittenbogaart CH.

AIDS Res Hum Retroviruses. 2020 Feb;36(2):122-130. doi: 10.1089/AID.2019.0160. Epub 2019 Nov 4.

PMID:
31571497
3.

Acute HIV Infection in Youth: Protocol for the Adolescent Trials Network 147 (ATN147) Comprehensive Adolescent Research and Engagement Studies (CARES) Study.

Nielsen-Saines K, Mitchell K, Kerin T, Fournier J, Kozina L, Andrews B, Cortado R, Bolan R, Flynn R, Rotheram MJ, Abdalian SE, Bryson Y; Adolescent Medicine Trials Network (ATN) CARES Team; Mobilizing Minds Research Group.

JMIR Res Protoc. 2019 Jan 16;8(1):e10807. doi: 10.2196/10807.

4.

The future of careers in pediatric infectious diseases: a call to action.

Spearman P, Bryson YJ.

Curr Opin Pediatr. 2019 Feb;31(1):144-147. doi: 10.1097/MOP.0000000000000723. Review.

PMID:
30531403
5.

Congenital Cytomegalovirus and HIV Perinatal Transmission.

Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson LM, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Machado DM, Ceriotto M, Morgado MG, Bryson YJ, Veloso VG, Grinsztejn B, Mirochnick M, Moye J, Nielsen-Saines K; MPH for the NICHD HPTN 040 Study Team.

Pediatr Infect Dis J. 2018 Oct;37(10):1016-1021. doi: 10.1097/INF.0000000000001975.

6.

Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission.

Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts DH, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado DM, Bryson YJ, Grinsztejn B, Moye J, Klausner JD, Bristow CC, Dickover R, Mirochnick M, Nielsen-Saines K; NICHD HPTN 040 Study Team.

PLoS One. 2018 Jan 5;13(1):e0189851. doi: 10.1371/journal.pone.0189851. eCollection 2018.

7.

Human Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs Enrolled in a Large Perinatal Study.

Yeganeh N, Kerin T, Ank B, Watts DH, Camarca M, Joao EC, Pilotto JH, Veloso VG, Bryson Y, Gray G, Theron G, Dickover R, Morgado MG, Santos B, Kreitchmann R, Mofenson L, Nielsen-Saines K.

Clin Infect Dis. 2018 May 17;66(11):1770-1777. doi: 10.1093/cid/cix1104.

8.

Advances, innovations, and challenges for new and old infections of children and adolescents.

Bryson YJ.

Curr Opin Pediatr. 2018 Feb;30(1):100-104. doi: 10.1097/MOP.0000000000000583. No abstract available.

PMID:
29227298
9.

Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection.

Adachi K, Xu J, Ank B, Watts DH, Mofenson LM, Pilotto JH, Joao E, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Gray G, Theron G, Morgado MG, Bryson YJ, Veloso VG, Klausner JD, Moye J, Nielsen-Saines K; NICHD HPTN 040 Study Team.

Clin Infect Dis. 2017 Aug 1;65(3):405-413. doi: 10.1093/cid/cix222.

10.

Zika virus congenital syndrome, the new Z in TORCHZ? Prospects for diagnosis prevention and treatment.

Bryson Y.

Curr Opin Pediatr. 2017 Feb;29(1):94-96. doi: 10.1097/MOP.0000000000000453. No abstract available.

PMID:
28027061
11.

Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant Women and Adverse Infant Outcomes.

Adachi K, Klausner JD, Xu J, Ank B, Bristow CC, Morgado MG, Watts DH, Weir F, Persing D, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado DM, Bryson YJ, Grinsztejn B, Bastos FI, Siberry G, Nielsen-Saines K; NICHD HPTN 040 Study Team.

Pediatr Infect Dis J. 2016 Aug;35(8):894-900. doi: 10.1097/INF.0000000000001199.

12.

Recent progress and new challenges in pediatric infectious disease.

Bryson YJ.

Curr Opin Pediatr. 2016 Feb;28(1):79-80. doi: 10.1097/MOP.0000000000000314. No abstract available.

PMID:
26735717
13.

Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study.

Yeganeh N, Watts HD, Camarca M, Soares G, Joao E, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata M, Ceriotto M, Machado DM, Grinzstejn B, Veloso VG, Morgado MG, Bryson Y, Mofenson LM, Nielsen-Saines K; NICHD HPTN 040P1043 Study Team.

Pediatr Infect Dis J. 2015 Mar;34(3):e52-7. doi: 10.1097/INF.0000000000000578. Erratum in: Pediatr Infect Dis J. 2015 Sep;34(9):1038. Grinsztejn, Beatriz [corrected to Grinzstejn, Beatriz].

14.

Raltegravir pharmacokinetics in neonates following maternal dosing.

Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316.

15.

Taking care of the caretakers to enhance antiretroviral adherence in HIV-infected children and adolescents.

Bryson Y.

J Pediatr (Rio J). 2014 Nov-Dec;90(6):533-5. doi: 10.1016/j.jped.2014.08.001. Epub 2014 Aug 13. No abstract available.

16.

Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.

Hoffman RM, Leister E, Kacanek D, Shapiro DE, Read JS, Bryson Y, Currier JS.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):593-601. doi: 10.1097/QAI.0b013e31829b0b9f.

17.

Hematopoietic cell transplantation with cord blood for cure of HIV infections.

Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R.

Biol Blood Marrow Transplant. 2013 Mar;19(3):393-7. doi: 10.1016/j.bbmt.2012.10.017. Epub 2012 Oct 23.

18.

Amniotic fluid exhibits an innate inhibitory activity against HIV type 1 replication in vitro.

Farzin A, Boyer P, Ank B, Nielsen-Saines K, Bryson Y.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):77-83. doi: 10.1089/AID.2011.0355. Epub 2012 Dec 7.

19.

Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.

Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado D, Bethel J, Morgado MG, Dickover R, Camarca M, Mirochnick M, Siberry G, Grinsztejn B, Moreira RI, Bastos FI, Xu J, Moye J, Mofenson LM; NICHD HPTN 040/PACTG 1043 Protocol Team.

N Engl J Med. 2012 Jun 21;366(25):2368-79. doi: 10.1056/NEJMoa1108275.

20.

Derivation of non-infectious envelope proteins from virions isolated from plasma negative for HIV antibodies.

Vyas GN, Stoddart CA, Killian MS, Brennan TV, Goldberg T, Ziman A, Bryson Y.

Biologicals. 2012 Jan;40(1):15-20. doi: 10.1016/j.biologicals.2011.11.005. Epub 2011 Dec 20.

21.

Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, Moye J, Bryson Y, Mofenson L, Camarca M, Watts DH; NICHD HPTN 040/PACTG 1043 PROTOCOL Team.

Pediatr Infect Dis J. 2011 Sep;30(9):769-72. doi: 10.1097/INF.0b013e3182242950.

22.

Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers.

Truong HM, Sim MS, Dillon M, Uittenbogaart CH, Dickover R, Plaeger SF, Bryson YJ.

Clin Vaccine Immunol. 2010 Dec;17(12):2024-8. doi: 10.1128/CVI.00088-10. Epub 2010 Oct 27.

23.

HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil.

Veloso VG, Bastos FI, Portela MC, Grinsztejn B, João EC, Pilotto JH, Araújo AB, Santos BR, Fonseca RC, Kreitchmann R, Derrico M, Friedman RK, Cunha CB, Morgado MG, Saines KN, Bryson YJ.

Rev Saude Publica. 2010 Oct;44(5):803-11. Epub 2010 Sep 8.

24.

Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.

Ching N, Nielsen-Saines KA, Deville JG, Wei LS, Garratty E, Bryson YJ.

AIDS Res Hum Retroviruses. 2010 May;26(5):585-91. doi: 10.1089/aid.2008.0274.

25.

Modeling vertical transmission of HIV: imperfect vaccines can be of benefit.

Sim MS, Cumberland WG, Duan N, Bryson YJ.

Vaccine. 2009 Nov 23;27(50):7003-10. doi: 10.1016/j.vaccine.2009.09.074. Epub 2009 Oct 1.

26.

A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.

Johnston SH, Lobritz MA, Nguyen S, Lassen K, Delair S, Posta F, Bryson YJ, Arts EJ, Chou T, Lee B.

J Virol. 2009 Nov;83(21):11016-26. doi: 10.1128/JVI.01242-09. Epub 2009 Aug 19.

27.

Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.

Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP.

HIV Clin Trials. 2009 Jan-Feb;10(1):41-7. doi: 10.1310/hct1001-041.

PMID:
19362995
28.

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team.

HIV Clin Trials. 2008 Mar-Apr;9(2):115-25. doi: 10.1310/hct0902-115.

29.

Nevirapine concentrations in newborns receiving an extended prophylactic regimen.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y; NICHD/HPTN 040/PACTG 1043 Protocol Team.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7.

PMID:
18398973
30.

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.

Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group.

Antimicrob Agents Chemother. 2007 Dec;51(12):4297-302. Epub 2007 Sep 24.

31.

Pharmacokinetics of oral zidovudine administered during labour: a preliminary study.

Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandía J, Hitti J, Bardeguez A, Rathore MH, Gonzalez Garcia A, Cababasay M, Samson P, Mofenson L, Bryson YJ, Dorenbaum A.

HIV Med. 2007 Oct;8(7):451-6.

32.

Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy.

Ching N, Yang OO, Deville JG, Nielsen-Saines K, Ank BJ, Sim MS, Bryson YJ.

Pediatr Res. 2007 Jun;61(6):692-7.

PMID:
17426646
33.

Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART).

Ching N, Deville JG, Nielsen KA, Ank B, Wei LS, Sim MS, Wolinsky SM, Bryson YJ.

Eur J Pediatr. 2007 Jan;166(1):51-6. Epub 2006 Jul 26.

PMID:
16868780
34.
35.

Interferon-gamma decreases replication of primary R5 HIV-1 isolates in thymocytes.

Pedroza-Martins L, Boscardin WJ, Anisman-Posner DJ, Redsar BN, Bryson YJ, Yang OO, Uittenbogaart CH.

AIDS. 2006 Apr 4;20(6):939-42.

PMID:
16549983
36.

Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins.

Yang OO, Church J, Kitchen CM, Kilpatrick R, Ali A, Geng Y, Killian MS, Sabado RL, Ng H, Suen J, Bryson Y, Jamieson BD, Krogstad P.

J Virol. 2005 Dec;79(24):15368-75.

37.

Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.

Mirochnick M, Stek A, Acevedo M, Keller M, Holland D, Capparelli E, Connor J, Huang S, Hughes M, Watts H, Mofenson L, Bryson Y.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):189-94.

PMID:
15905735
38.

Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants.

Pedroza-Martins L, Boscardin WJ, Anisman-Posner DJ, Schols D, Bryson YJ, Uittenbogaart CH.

J Virol. 2002 Jul;76(14):6929-43.

39.

Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, O'Sullivan MJ, Scott G, Stek AM, Wara D, Bulterys M.

N Engl J Med. 2002 Jun 13;346(24):1863-70.

40.

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.

McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, Frenkel LM, Yogev R, Gigliotti F, Luzuriaga K, Livingston RA; AIDS Clinical Trials Group 230 Collaborators.

J Infect Dis. 2001 Nov 15;184(10):1331-5. Epub 2001 Oct 10.

PMID:
11679925
41.

Perinatal Transmission of HIV: Recognition and Treatment Interventions.

Deville J, Bryson Y.

Curr Infect Dis Rep. 2001 Aug;3(4):388-396.

PMID:
11470031
42.
43.
44.

Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.

Equils O, Garratty E, Wei LS, Plaeger S, Tapia M, Deville J, Krogstad P, Sim MS, Nielsen K, Bryson YJ.

J Infect Dis. 2000 Sep;182(3):751-7. Epub 2000 Aug 15.

PMID:
10950768
45.

Pneumococcal and influenza immunization and human immunodeficiency virus load in children.

Keller M, Deveikis A, Cutillar-Garcia M, Gagajena A, Elkins K, Plaeger S, Bryson Y, Kaplan A, Zangwill K, Chang SJ.

Pediatr Infect Dis J. 2000 Jul;19(7):613-8.

PMID:
10917218
46.

Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.

Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, Van Dyke R, Jimenez E.

J Infect Dis. 2000 Mar;181(3):890-6.

PMID:
10720509
47.

Diagnosis of HIV infection in children.

Nielsen K, Bryson YJ.

Pediatr Clin North Am. 2000 Feb;47(1):39-63. Review.

PMID:
10697641
48.

Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).

Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, Wara D, Bryson YJ, Starr SE, Petru A, Burchett S.

J Infect Dis. 2000 Feb;181(2):548-54.

PMID:
10669338
49.

Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Study Group.

Shearer WT, Lipshultz SE, Easley KA, McIntosh K, Pitt J, Quinn TC, Kattan M, Goldfarb J, Cooper E, Bryson Y, Kovacs A, Bricker JT, Peavy H, Mellins RB, Heart N, Institute LB.

Pediatrics. 2000 Jan;105(1):e9.

50.

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M, Jung D, Spector SA, Bryson Y.

Clin Infect Dis. 1999 May;28(5):1109-18.

PMID:
10452644

Supplemental Content

Loading ...
Support Center